Patient description: The patient is a 35-year-old woman with myasthenia gravis, class IIa. She complains of diplopia and fatigue and weakness that affects mainly her upper limbs. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She takes pyridostigmine 60 mg three times a day. But she still has some symptoms that interfere with her job. She is a research coordinator and has 3 children. Her 70-year-old father has hypertension. She does not smoke or use illicit drugs. She drinks alcohol occasionally at social events. Her physical exam and lab studies were not remarkable for any other abnormalities. BP: 110/75 Hgb: 11 g/dl WBC: 8000 /mm3 Plt: 300000 /ml Creatinine: 0.5 mg/dl BUN: 10 mg/dl Beta hcg: negative for pregnancy

Clinical trial eligibility criteria: eligible ages (years): 18.0-64.0,  Myasthenia Gravis Male and female subjects, with ocular and generalised myasthenia gravis (grade 1-2-3) Between the ages of 18 and 64 years, inclusive, at the time of the first injection A Body Mass Index (BMI) between 18 and 35 kg/m2, inclusive Patient with positive antibodies to AChR based on radioimmunoassay(RIA) (AChRAb ≥ 1 nmol/l); if available, historical data on AChR Ab levels over the last 2 years will be collected in the study records Patient may use corticosteroid treatment, equivalent to a daily dose of 30 mg prednisone or lower and stable (dose +/ mg) during the 3 months before participation Patient may use one immunosuppressive drug with or without concomitant use of corticosteroid, providing that the dosage has been stable/unchanged for 3 months before participation Blood pressure and heart rate (supine & standing) within normal reference range for the population or investigator site, or results with acceptable deviations that are judged to be not clinically significant by the investigator Venous access sufficient to allow blood sampling as per the protocol Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures  MG patients of Grade 4 or 5 based on myasthenia gravis foundation of America (MGFA) classification Patients with history or presence of a primary or recurrent malignant disease including the presence or history of a thymoma Thymectomy planned during part A of the study period or performed within 1 year prior to the first dose of study vaccine Any confirmed or suspected immunosuppressive or immunodeficient condition not related to the treatment of MG, including human immunodeficiency virus (HIV) infection, or a family history of congenital or hereditary immunodeficiency History or evidence of administration of immunoglobulins and/or any blood products within 3 months prior to the first dose of study vaccine or a planned administration of immunoglobulins during the first 3 months of the trial History or evidence of rituximab treatment within 6 months prior to first dose of study vaccine History or evidence of plasmapheresis within 3 months prior to the first dose of study vaccine or a planned plasmapheresis during the first 3 months of the trial At high risk for aspiration Pulmonary: forced vital capacity reduced to less than 70% of predicted capacity History of severe allergic disease or reactions likely to be exacerbated by any component of the vaccine